Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute migraine attacks Age: Adult |
Dose: Oral – Initially 2.5 mg Frequency: as needed Note: A second dose may be taken at least 2 hours after the first dose if symptoms recur within 24 hours. Maximum dose: 10 mg in 24 hours. Safety of treating greater than three headaches in a 30-day period has not been established. |
|
Indication: Acute migraine attacks Age: Adult Condition: Hepatic impairment |
Dose: Oral – Dose reduction may be needed Note: Dose reduction may be needed with blood pressure monitoring. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute treatment of migraine with or without aura Age: 12 years and older |
Dose: Nasal spray – 2.5 mg Frequency: May repeat after 2 hours if migraine has not resolved or returns Note: Maximum Dose: 10 mg in any 24-hour period |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Severe renal impairment (Creatinine Clearance greater than or equal to 5 to less than or equal to 25 mL/min) |
Dose: Tablet Note: Renal clearance was reduced by 25% compared to the normal group (Creatinine Clearance greater than or equal to 70 mL/min) after oral dosing |
|
Condition: Moderate renal impairment (Creatinine Clearance greater than or equal to 26 to less than or equal to 50 mL/min) |
Dose: Tablet Note: No significant change in renal clearance was observed |
Administration
- Can be taken with or without food
- Take at first sign of migraine
Side Effect
- Dizziness (6-10%)
- Neck/throat/jaw pain (4-10%)
- Parasthesia (5-9%)
- Nausea (4-9%)
- Weakness (3-9%)
- Somnolence (5-8%)
- Warm/cold sensation (5-7%)
- Xerostomia (3-5%)
- Chest pain (2-4%)
- Diaphoresis (3%)
- Pain (2-3%)
- Dyspepsia (1-3%)
- Dysphagia (2%)
- Myasthenia (2%)
- Palpation (2%)
- Vertigo (2%)
- Hypoesthesia (1-2%)
- Myalgia (1-2%)
- QT prolongation
- Bradycardia
- Tachycardia
- Thrombophlebitis
- Postural hypotension
- Hyperglycemia
- Alk phos increased
- Arthritis
- Twitching
- Myocardial infarction and artery vasospasm in patients with CAD risk factors
- Cardiac arrhythmias
- MI
- subarachnoid haemorrhage
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
SSRI, selective serotonin- and norepinephrine-reuptake inhibitors (SNRI)
|
Increased risk of serotonin syndrome
|
|
Cimetidine, quinolone antibacterials, CYP1A2 inhibitors
|
Increased zolmitriptan concentrations
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Coronary Artery Disease
|
Risk of heart attack
|
|
Previous Cerebrovascular Accident
|
Risk of stroke
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Protect from light and moisture, store below 30°C. Keep the medicine out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.